Treatment Information

Back

Lung Cancer treatment details. Chemotherapy.

Rush University Medical Center, Chicago, IL, United States.

Survival: monthsCountry:United States
Toxiciy Grade:4City/State/Province:Chicago, IL
Treatments:ChemotherapyHospital:Rush University Medical Center
Drugs:Journal:Link
Date:May 2008

Description:

Patients: This phase III study involved 849 patients with non-small-cell lung cancer. The majority of patients (over 70%) were men, and they ranged in age from 30 to 87 years of age.

Treatment: Patients were treated with either paclitaxel poliglumex or docetaxel. These are both chemotherapy drugs.

Toxicities: Grade 3 or 4 neutropenia was reported in 37% of patient treated with docetaxel and 14% of patients treated with paclitaxel poliglumex. Alopecia occurred more often in patients treated with docetaxel, while neuropathy and hypersensitivity reactions were more common in patients receiving paclitaxel poliglumex. No grade 3 or more severe toxicities were reported in patients treated with paclitaxel poliglumex.

Results: The median overall survival was 6.9 months in both treatment groups.

Correspondence: Dr. P. Bonomi



Back